stockrow
Monday 9 November 2026
Export YARW’s income statement to Excel — free account
Yarrow Bioscience, Inc
YARWYarrow Bioscience, Inc’s revenue for fiscal 2025 (year ended December 2025) was $570,000.00, up 13.8% from fiscal 2024.
- Revenue
- +40.6%
- EPS
- +46.0%
- Free cash flow
- +81.6%
Quarter to June 2026, against a year earlier
15.60
2.00
+14.71%
Follow YARW
Alert me
Yarrow Bioscience, Inc (YARW) P/E ratio
Yarrow Bioscience, Inc has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 31 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CMPX Compass Therapeutics, Inc. compare | n/m |
| SPRB Spruce Biosciences, Inc. compare | n/m |
| MOLN Molecular Partners AG Sponsored ADR compare | n/m |
| YARW Yarrow Bioscience, Inc | n/m |
| TARA Protara Therapeutics, Inc. compare | n/m |
| CUE Cue Biopharma, Inc. compare | n/m |
| PDSB PDS Biotechnology Corporation compare | n/m |
| MSLE Satellos Bioscience Inc. compare | n/m |
| MENS Jyong Biotech Ltd. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)